Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin and hypertonic saline for non-cystic fibrosis bronchiectasis
ACTRN12611001199909Phase 3Recruiting
- Sponsor
- Sydney Local Health District
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azithromycin and hypertonic saline in bronchiectasis (4 arms), sponsored by Sydney Local Health District. Primary endpoint: Quality of life measured by St George Respiratory Questionnaire at Month 7. Started Nov 2011; status: recruiting.
02
Drugs
azithromycinhypertonic saline
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ACTRN12611001199909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001199909.